Federal drug review nettles biotech industry
Concern evident on eve of Boston expo
Federal regulators found themselves under the spotlight Monday as the massive Biotechnology Industry Organization’s annual convention opened in Boston. As more than 15,000 life-sciences professionals converged on the Boston Convention and Exhibition Center for four days of panels and networking, a Food and Drug Administration plan to make decisions on new drugs more transparent and consistent drew criticism. Drug makers have long complained about what they consider a needlessly complicated review process. But an FDA-proposed framework did little to quiet concerns.